GlassScriptPhysician profile
Shaun Xiao
NPI 1063726206
$3,317.93
in general payments reported to CMS, 2019-2025
36 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2021: $146 · 2022: $623 · 2023: $1,260 · 2024: $708 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.33 |
| Education | $209.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $673.98 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $644.98 | 2022-2025 | Enhertu, Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $218.91 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $198.07 | 2022-2024 | Darzalex, Tecvayli, Imbruvica |
| Daiichi Sankyo INC. | $186.76 | 2023-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $156.01 | 2019-2024 | Padcev |
| Ethicon INC. | $133.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $111.40 | 2022-2025 | |
| Eisai INC. | $110.10 | 2022-2025 | |
| Pfizer INC. | $70.94 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Abbvie INC. | $55.28 | 2025 | |
| Gilead Sciences, INC. | $47.09 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.68 | 2023-2024 | Alunbrig |
| Exelixis INC. | $43.94 | 2022-2024 | Cabometyx |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $43.36 | 2023-2025 | Orserdu |
| Mirati Therapeutics, INC. | $41.20 | 2023 | Krazati |
| Genzyme Corporation | $41.17 | 2022-2023 | |
| Lilly USA, LLC | $37.99 | 2023-2024 | Jaypirca, Verzenio |
| Genentech USA, INC. | $37.66 | 2023 | Tecentriq, Phesgo, Perjeta |
| Beigene USA, INC. | $36.90 | 2022-2023 | Brukinsa |
| Sumitomo Pharma America, INC. | $36.62 | 2024-2025 | Orgovyx |
| Incyte Corporation | $33.56 | 2023-2024 | Jakafi |
| Myovant Sciences INC. | $32.34 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $23.88 | 2023 | Imbruvica |
| Veracyte, INC. | $21.77 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.87 | 2024 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $18.97 | 2022 | |
| Tempus Ai, INC | $18.24 | 2024 | |
| Celgene Corporation | $17.30 | 2025 | Reblozyl |
| Amgen INC. | $17.10 | 2023 | Evenity, Prolia |
| Cti Biopharma Corp. | $16.86 | 2023 | Vonjo |
| Blueprint Medicines Corporation | $16.19 | 2022 | |
| Emd Serono, INC. | $14.50 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $13.87 | 2024 | Libtayo |
| Seagen INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Xiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.